



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 04/21/2022 18:18
Last Report Issued 04/04/2022 06:28

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3260SP-POS
Patient ID 3260SP-POS
Chain 22000500
DOB Not Given
Sex Not Given
Workorder 22000500
Received 01/25/2022

Lab ID 22000500-001
Matrix Serum or Plasma
Patient Name 3260SP-POS
Patient ID 3260SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

3260SP Oxazepam, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Oxazepam	50	ng/mL	20	
----------	----	-------	----	--

Synonym(s): Serax®

When used as a drug, the therapeutic plasma concentration: 200-1400 ng/mL.
Potentially toxic greater than 2000 ng/mL.

As a metabolite of Diazepam, low concentrations may be observed. In one study, following chronic daily doses of about 70 mg of Diazepam, the steady-state serum concentrations were 50-400 ng Oxazepam/mL.

As a metabolite of Temazepam, low concentrations may be observed.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.